SymbioCellTech Company Research Report
Company Overview
- Name: SymbioCellTech LLC
- Mission: To provide a functional cure for patients suffering from Type 1 Diabetes.
- Founded: No specific information on the founding date is available.
- Founder: Founded by Dr. Christof Westenfelder.
- Key People:
- Dr. Christof Westenfelder - Founder and Chief Executive Officer
- Dr. Axel Zander - Co-founder and Vice President
- Dr. Anna Gooch - Chief Scientific Officer
- Travis Manning - Chief Operating Officer / Controller
- Dr. Leanne Swenson - Chief Medical Officer
- Dr. Eric Goskink - Strategic Advisor
- Headquarters: 615 Arapeen Drive, Salt Lake City, UT, 84108, United States
- Number of Employees: No information is available.
- Revenue: No information is available.
- Known For: Development of Neo-Islet technology, a stem cell-enabled therapy for Type 1 Diabetes.
Products
- Neo-Islets
- Description: Neo-Islets are hybrid clusters of allogeneic Pancreatic Beta Cells and Mesenchymal Stem Cells (MSCs) used for stem cell-based therapy for Type 1 Diabetes.
- Key Features:
- Provides physiologic insulin secretion.
- Achieves euglycemia in hosts.
- Offers immune isolation from destructive immunosurveillance.
- Addresses four major technical challenges: immune attack, donor scarcity, vascularization, and physiologic insulin delivery.
Recent Developments
- Recent Developments:
- Stem Cell-Enabled Therapy announced as an innovation for Type 1 Diabetes without the need for anti-rejection drugs (9/19/24).
- Joined Startup Health’s Type 1 Diabetes Moonshot Fellowship (9/17/24).
- Neo-Islets won the Innovation Challenge at the American Diabetes Association (ADA) Scientific Session (6/24/24).
- SymbioCellTech was honored as Runner-Up at the 2023 Medical & Health Med Tech Innovation Awards (10/23/23).
- Exclusive option agreement with Virbac for development in companion animals (1/12/21).
- New Products Launched: No new products explicitly mentioned.
- New Features Added to Existing Products: No specific features mentioned beyond the ongoing development of Neo-Islet technology.
- New Partnerships:
- Partnership with Virbac for technology development for Type 1 Diabetes treatment in companion animals (1/12/21).
This report is a comprehensive collection of existing data on SymbioCellTech LLC, focusing on the company's structure, innovative products, and recent achievements, capturing the company's pivotal role in diabetes treatment advancements.
